biotech · Lung Cancer · Non-small Cell Lung Cancer (NSCLC) · RVMD
Revolution Medicines
Revolution Medicines clinical programs — 10 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 700 Saginaw Dr., Redwood City, California 94063, US
- Founded
- 2014
- Employees
- 1,050
- Programs
- 26
- Drugs
- 28
- Patents
- 36
Revolution Medicines projects
10 ClinicalTrials.gov programs sponsored by Revolution Medicines.
Revolution Medicines has 10 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Daraxonrasib
Revolution Medicines
Advanced Solid Tumors
1 trial -
Elironrasib
Revolution Medicines
Non-Small Cell Lung Cancer (NSCLC)
1 trial -
RMC-4630
Revolution Medicines
Non-Small Cell Lung Cancer
1 trial -
RMC-4630
Revolution Medicines
Solid Tumor
1 trial -
RMC-6236
Revolution Medicines
Non-small Cell Lung Cancer (NSCLC)
1 trial -
RMC-6236
Revolution Medicines
Colorectal Cancer
1 trial -
RMC-9805
Revolution Medicines
Lung Cancer
1 trial -
RMC-LUNG-101C
Revolution Medicines
Lung Cancer
1 trial -
TNG462
Revolution Medicines
PDAC
1 trial -
Vociprotafib
Revolution Medicines
Metastatic Neoplasm
1 trial
Frequently asked questions
How many clinical projects does Revolution Medicines have?
10 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.